Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 6Neoplasms 3Carcinoma, Transitional Cell 3Carcinoma in Situ 3Virus Diseases 1Urologic Neoplasms 1Urologic Diseases 1Urogenital Neoplasms 1Urinary Bladder Diseases 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms by Site 1Adenoviridae Infections 1

Interventions

Mitomycin 3vofatamab 2pembrolizumab 2Nivolumab 2Gemcitabine 2Cisplatin 2B701 protein, Human herpesvirus 6 2valrubicin 1tislelizumab 1relatlimab 1enzalutamide 1enfortumab vedotin 1durvalumab 1Water 1Urinary Diversion 1Standard of Care 1Radiosurgery 1Radiation Dose Hypofractionation 1Multiparametric Magnetic Resonance Imaging 1Immunonutrition Diet 1Immune Checkpoint Inhibitors 1Gels 1Fluorouracil 1Docetaxel 1Cystoscopy 1Cystectomy 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Urinary Bladder Diseases × valrubicin × Clear all
NCT01310803 2017-10-05

Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder

Endo Pharmaceuticals

Phase 3 Terminated
1 enrolled 5 charts
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡